Krystal Biotech (KRYS) Interest Coverage Ratio (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Interest Coverage Ratio of 0.12 for Q2 2026, down 63.47% year-over-year from 0.34 in Q2 2025, and down 34.52% on a QoQ basis from 0.19 in Q1 2026.
Krystal Biotech (KRYS) Interest Coverage Ratio (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Interest Coverage Ratio for 11 years, with the latest figure at 0.12 in Q2 2026.
- Interest Coverage Ratio for Q2 2026 came in at 0.12, down 63.47% year-over-year; the trailing twelve-month figure through Jun 2026 was 0.42 (down 65.07% YoY), and the FY2025 annual result was 0.54, up 28.47% from the prior year.
- Interest Coverage Ratio slipped to 0.12 in Q2 2026, from 0.19 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.34 in Q2 2025 and troughed at 1.65 in Q1 2022.
- A 5-year average of 0.18 and a median of 0.04 in 2024 frame the typical range for Interest Coverage Ratio.
- The widest annual swing landed in 2022, when Interest Coverage Ratio tumbled 250.84%; it then surged 1125.0% in 2024.
- A 5-year view of Interest Coverage Ratio shows it stood at 0.85 in 2022, then jumped by 102.56% to 0.02 in 2023, then surged by 1125.0% to 0.26 in 2024, then tumbled by 43.97% to 0.15 in 2025, then declined by 17.1% to 0.12 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 0.12 in Q2 2026, 0.19 in Q1 2026, and 0.15 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.12 |
| Mar 31, 2026 | 0.19 |
| Dec 31, 2025 | 0.15 |
| Sep 30, 2025 | 0.23 |
| Jun 30, 2025 | 0.34 |
| Mar 31, 2025 | 0.18 |
| Dec 31, 2024 | 0.26 |
| Sep 30, 2024 | 0.11 |
| Jun 30, 2024 | 0.04 |
| Mar 31, 2024 | -0.03 |
| Dec 31, 2023 | 0.02 |
| Sep 30, 2023 | -0.19 |
| Jun 30, 2023 | -0.22 |
| Mar 31, 2023 | -0.74 |
| Sep 30, 2022 | -0.85 |
| Jun 30, 2022 | -1.01 |
| Mar 31, 2022 | -1.65 |
| Sep 30, 2021 | -1.66 |
| Jun 30, 2021 | -0.72 |
| Mar 31, 2021 | -0.47 |